These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17338675)

  • 1. Vasopressin antagonists in the management of heart failure.
    Rossi J; Orlandi C; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):323-30. PubMed ID: 17338675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of tolvaptan in acute decompensated heart failure.
    Ho JE; Teerlink JR
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):601-8. PubMed ID: 18510477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
    Chen S; Jalandhara N; Batlle D
    Nat Clin Pract Nephrol; 2007 Feb; 3(2):82-95. PubMed ID: 17251996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin-receptor antagonists.
    Hoorn EJ; Zietse R
    Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP; Balk RA
    Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
    Rossi J; Bayram M; Udelson JE; Lloyd-Jones D; Adams KF; Oconnor CM; Stough WG; Ouyang J; Shin DD; Orlandi C; Gheorghiade M
    Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH; Serrano C
    Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure].
    de Groote P
    Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
    Goldsmith SR
    Am J Med; 2006 Jul; 119(7 Suppl 1):S93-6. PubMed ID: 16843092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When is it appropriate to use vasopressin receptor antagonists?
    Lehrich RW; Greenberg A
    J Am Soc Nephrol; 2008 Jun; 19(6):1054-8. PubMed ID: 18337478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
    Cavalcante JL; Khan S; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of vasopressin receptor antagonists in hyponatremia.
    Khanna A; Menon MC
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyponatremia in heart failure.
    Chatterjee K
    J Intensive Care Med; 2009; 24(6):347-51. PubMed ID: 19850560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.